HUP0100427A3 - Ace inhibitor-mmp inhibitor combinations - Google Patents

Ace inhibitor-mmp inhibitor combinations

Info

Publication number
HUP0100427A3
HUP0100427A3 HU0100427A HUP0100427A HUP0100427A3 HU P0100427 A3 HUP0100427 A3 HU P0100427A3 HU 0100427 A HU0100427 A HU 0100427A HU P0100427 A HUP0100427 A HU P0100427A HU P0100427 A3 HUP0100427 A3 HU P0100427A3
Authority
HU
Hungary
Prior art keywords
inhibitor
combinations
mmp
ace
ace inhibitor
Prior art date
Application number
HU0100427A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100427(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0100427A2 publication Critical patent/HUP0100427A2/hu
Publication of HUP0100427A3 publication Critical patent/HUP0100427A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0100427A 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations HUP0100427A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (2)

Publication Number Publication Date
HUP0100427A2 HUP0100427A2 (hu) 2001-06-28
HUP0100427A3 true HUP0100427A3 (en) 2002-11-28

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100427A HUP0100427A3 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Country Status (24)

Country Link
US (1) US6133304A (hu)
EP (1) EP1047450B1 (hu)
JP (1) JP2001526245A (hu)
KR (1) KR20010033473A (hu)
AR (1) AR015504A1 (hu)
AT (1) ATE225187T1 (hu)
AU (1) AU751701B2 (hu)
BR (1) BR9814422A (hu)
CA (1) CA2305436A1 (hu)
CO (1) CO4970775A1 (hu)
DE (1) DE69808518T2 (hu)
DK (1) DK1047450T3 (hu)
ES (1) ES2184340T3 (hu)
HU (1) HUP0100427A3 (hu)
IL (1) IL135428A0 (hu)
IS (1) IS5446A (hu)
NO (1) NO20003256D0 (hu)
NZ (1) NZ503962A (hu)
PE (1) PE20000065A1 (hu)
PL (1) PL341335A1 (hu)
PT (1) PT1047450E (hu)
UY (1) UY25321A1 (hu)
WO (1) WO1999032150A1 (hu)
ZA (1) ZA9811794B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12462001A3 (sk) * 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1425010B8 (en) 2001-01-29 2012-03-28 Janssen Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
EP1419767A4 (en) * 2001-08-20 2005-03-16 Ono Pharmaceutical Co MEDICINE FOR TREATMENT OF HEART FAILURE
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (en) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
PL1684719T3 (pl) * 2003-11-14 2012-11-30 Baxalta Inc Kompozycje alfa 1-antytrypsyny i sposoby leczenia z zastosowaniem takich kompozycji
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CA2575928A1 (en) * 2004-08-02 2006-02-09 Genmedica Therapeutics Sl Compounds for inhibiting copper-containing amine oxidases and uses thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CN102159211A (zh) * 2008-06-20 2011-08-17 金尼医疗公司 用于治疗纤维化疾病或病症的组合物
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011041545A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
EA032526B1 (ru) 2011-08-30 2019-06-28 Схди Фаундейшн, Инк. Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9106438A (pt) * 1990-05-11 1993-05-18 Pfizer Composicoes terapeuticas sinergisticas e processos
EP0808172B1 (en) * 1995-02-10 2003-06-25 G.D. SEARLE & COMPANY Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy
CN1077885C (zh) * 1996-05-17 2002-01-16 沃尼尔·朗伯公司 联苯基磺酰胺基质金属蛋白酶抑制剂
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
AR015504A1 (es) 2001-05-02
ES2184340T3 (es) 2003-04-01
US6133304A (en) 2000-10-17
KR20010033473A (ko) 2001-04-25
PE20000065A1 (es) 2000-02-11
JP2001526245A (ja) 2001-12-18
ZA9811794B (en) 1999-06-29
CO4970775A1 (es) 2000-11-07
AU751701B2 (en) 2002-08-22
WO1999032150A1 (en) 1999-07-01
CA2305436A1 (en) 1999-07-01
EP1047450B1 (en) 2002-10-02
NO20003256L (no) 2000-06-22
DK1047450T3 (da) 2003-01-27
NO20003256D0 (no) 2000-06-22
IS5446A (is) 2000-04-14
AU1522099A (en) 1999-07-12
EP1047450A1 (en) 2000-11-02
DE69808518D1 (de) 2002-11-07
PL341335A1 (en) 2001-04-09
UY25321A1 (es) 2004-07-30
NZ503962A (en) 2002-03-28
HUP0100427A2 (hu) 2001-06-28
IL135428A0 (en) 2001-05-20
BR9814422A (pt) 2000-10-10
PT1047450E (pt) 2003-02-28
ATE225187T1 (de) 2002-10-15
DE69808518T2 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
PL332497A1 (en) Reflux inhibitor
IL131661A0 (en) Protease inhibitors
EP0969840A4 (en) THROMBIN INHIBITORS
HUP0100427A3 (en) Ace inhibitor-mmp inhibitor combinations
PL336589A1 (en) Serinic protease inhibitors
EP0971891A4 (en) THROMBIN INHIBITORS
PL336856A1 (en) Protease inhibitors
ZA983841B (en) Protease inhibitors
PL331803A1 (en) Bidonoric metaloprotease inhibitors
ZA983522B (en) Protease inhibitors
ZA988479B (en) Protease inhibitors
GB2346885B (en) Phospholipase inhibitor
ZA988064B (en) Protease inhibitors
EP1017383A4 (en) THROMBIN INHIBITORS
EP0975612A4 (en) PROTEASE INHIBITORS
EP1039907A4 (en) THROMBIN INHIBITORS
SI1047450T1 (en) Ace inhibitor-mmp inhibitor combinations
EP1027333A4 (en) THROMBIN INHIBITORS
GB9707219D0 (en) Inhibitor
GB9717893D0 (en) Inhibitor
GB9709064D0 (en) Inhibitors
GB9727371D0 (en) Inhibitors